Transcriptogen
Bath
About Transcriptogen
Transcriptogen Ltd has developed a new approach to the treatment of cancer. The Company has developed a lead molecule, TSG1301, which has been shown to be highly effective at treating Breast and Pancreatic Cancer in human tumours that have been grafted onto mice. In addition, it appears to possess a very low toxicity, resulting in the potential for side-effect-free treatment of these cancers. The Company was established to exploit the growing interest in the use of small molecules to inhibit the transcription of disease-related genes. Transcription is the synthesis of RNA (‘messenger DNA’) from a DNA template, a process that occurs in cell division. Transcription Factors (‘TFs’) govern the growth of cancer cells and, when inhibited, cell death occurs. TFs work by binding to specific sequences of DNA within genes. Specific TFs are associated with specific cancers (e.g., the TF “NF╬║B” is associated with breast and pancreatic cancer). The Company’s TF inhibitors are targeted to these specific TFs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Series Unknown (May 2016)
- Website: transcriptogen.com
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/transcriptogen-2806318 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.